Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gene Therapy Trials and Tribulations

This article was originally published in Start Up

Executive Summary

The increased scrutiny of gene therapy by the National Institutes of Health and the Food and Drug Administration hasn't, to date, affected companies' clinical trials or long-term strategies, say executives of companies working in the field. This is partly because the NIH and FDA have yet to announce what new requirements, if any, companies must meet. Another reason is that few companies are working with adenoviral vectors--the focus of much attention following the death in September of an 18-year-old patient while in a gene therapy experiment.
Advertisement

Related Content

Cardiac Gene Therapy: Combination Products' Next Frontier?
Cardiac Gene Therapy: Combination Products' Next Frontier?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC090147

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel